AIDS (London, England)

(AIDS) ISSNs: 0269-9370,

References in AIDS (London, England):

Search this table:

Title	Authors	Year
The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme beta-polymerase.	Srivastava DK, Tendler CL, Milani D, English MA, Licht JD, Wilson SH	2001
Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.	Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, Ludaway T, McNaught J, Russ R, Stuart T, Santoianni R	2006
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations.	Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA	2007
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.	Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa ML, Frankel FA, Essex M, Wainberg MA	2006
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.	Brenner BG, Routy JP, Quan Y, Moisi DD, Oliveira M, Turner D, Wainberg MA	2004
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.	Klein MB, Campeol N, Lalonde RG, Brenner BG, Wainberg MA	2003
Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.	Winslow DL, Garber S, Reid C, Scarnati H, Baker D, Rayner MM, Anton ED	1996
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.	Brenner BG, Turner D, Oliveira M, Moisi DD, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA	2003
The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses.	Wei X, Liang C, Götte M, Wainberg MA	2002
Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy.	Paolucci S, Baldanti F, Tinelli M, Maga G, Gerna G	2003
HIV-1 nucleocapsid protein and replication protein A influence the strand displacement DNA synthesis of lentiviral reverse transcriptase.	Amacker M, Hottiger M, Mossi R, Hübscher U	1997
Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.	Salomon H, Wainberg MA, Brenner BG, Quan Y, Rouleau D, Coté P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP	2000
HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons.	Bernard NF, Pederson K, Chung F, Ouellet L, Wainberg MA, Tsoukas CM	1998
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.	Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J	1995
Transmission networks of drug resistance acquired in primary/early stage HIV infection.	Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA	2008
Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.	Cherry E, Morin N, Wainberg MA	1998
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.	Wainberg MA, Hsu M, Gu Z, Borkow G, Parniak MA	1996
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.	Ruiz L, Romeu J, Martínez-Picado J, Schmit JC, Vandamme AM, Balagué M, Cabrera C, Puig T, Tural C, Segura A, Sirera G, De Clercq E, Clotet B	1996
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.	Vermeire K, Princen K, Hatse S, De Clercq E, Dey K, Bell TW, Schols D	2004
Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells.	Balzarini J, Van Herrewege Y, Vanham G	2002
Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.	Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM	1999
How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors.	De Clercq E	1994
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.	Schmit JC, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sönnerborg A, Leal M, Harrer T, Clotet B, Arendt V, Lissen E, Witvrouw M, Desmyter J, De Clercq E, Vandamme AM	1998
Induction of apoptosis by primary HIV-1 isolates correlates with productive infection in peripheral blood mononuclear cells.	Zhang YJ, Fadeel B, Hodara V, Fenyö EM	1997
Differential inhibition of retroviral reverse transcriptase by poly(2-fluoroadenylic acid), a template analogue.	Kohda K, Ukai H, Balzarini J, De Clercq E, Torrence PF	1991

Showing 1 to 25 of 25 entries